ARRAY BIOPHARMA
   
 

Welcome to Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Seven Phase 3 or pivotal studies are already in progress, or are planned to begin, within the next year. These programs include the wholly-owned hematology drug, ARRY-520, for multiple myeloma and two partnered cancer drugs, selumetinib (AstraZeneca) and MEK162 (Novartis).

Latest News and Press Releases:
4/23/2014 Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2014 On April 29, 2014
4/23/2014 Binimetinib Continues To Advance In Clinical Development
3/3/2014 Array BioPharma Provides Clinical Update On ARRY-502 For Asthma At Scientific Meeting
2/18/2014 Array BioPharma To Present At The RBC Capital Markets Global Healthcare And Cowen Annual Healthcare Conferences
 
Email this page
Printer friendly version
   
The Street